USFDA issues EIR for Alkem Laboratories’ Baddi facility

31 Jul 2019

The US Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) for Alkem Laboratories’ manufacturing facility located at Baddi, which was inspected from May 13, 2019 to May 17, 2019. The inspection has now been closed by the USFDA. In response to the Form 483 issued by the USFDA containing four observations, the company had submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.

Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.

Related Alkem Laboratories Ltd. Links:

Alkem Laboratories Share Price

3046.65 17.00 (0.56%) May 11, 16:53
1 Year Price Chart
Company Name CMP
Sun Pharma Inds. 707.85
Dr. Reddys Lab 5293.60
Lupin 1197.60
Piramal Enterprises 1690.00
Cadila Healthcare 629.70
View more..
Sensex vs Alkem Laboratories
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323